Data investigation

The Add-On Menu

At our August 2026 count, 152 of 560 sellers ran a peptide menu. Ranked by how often items appear, it is almost exactly the inverse of a ranking by evidence, and the reason is commercial rather than clinical.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

Just over a quarter of the sellers we track (152 of 560) run a peptide menu alongside their GLP-1 offering, and 127 of those also publish GLP-1 prices. Ranked by how often they appear, the menu is almost exactly the inverse of a ranking by evidence.

What is on the menu

Most frequently offered peptides across 152 seller menus, against the human trial evidence for each.
ItemSellers offering itHuman randomized trials
NAD139None of the injected form
Sermorelin109From its history as a growth-hormone agent
Glutathione75Trials exist — in melasma and Parkinson’s, not weight or energy
GHK-Cu32Two
PT-141 (bremelanotide)29Fourteen — an approved drug
BPC-15715Zero
Tesamorelin11Twenty-six — an approved drug

Glutathione deserves a word, because “no evidence” would be wrong. It has a real randomized literature in skin lightening and melasma, in Parkinson’s disease, in autistic children with disruptive behavior and in sepsis. What it does not have is trials for the reasons it appears on these menus. Evidence for one use is not evidence for another, and a seller citing “studies” is not necessarily citing studies of what you are buying it for. The trials are taken one claim at a time in glutathione: what the evidence shows.

The two items with the most human trial evidence, tesamorelin and bremelanotide, both became approved drugs, and both sit near the bottom of the menu. The two at the top have the least. We set out the trial counts in what has human trials and what does not.

Ranked by evidence, the list nearly reverses.

Why the inversion makes commercial sense

This is not a conspiracy and it does not need one. The items at the top of the menu share properties that have nothing to do with whether they work.

  • They treat something everyone has. Energy, aging, recovery and general wellness have no diagnostic threshold, so nobody is excluded and nothing can fail.
  • They have no approved indication, which means no label, no approved claim, and therefore no claim that can be contradicted by one.
  • Nobody can tell whether they worked. Unlike a GLP-1, where the scale answers within weeks, an energy or longevity product is unfalsifiable at the individual level.
  • They are cheap to add. The consultation, the prescriber relationship and the shipping already exist, so an extra product is close to pure margin.

The items further down the menu are the opposite: they treat specific conditions, in specific people, with specific measurable outcomes. That makes them harder to sell to everyone, which is exactly why they appear less often.

The shape of a typical menu

The median menu carries three items; the longest we found carries twenty. A short menu of two or three is usually the top of the list above (NAD, sermorelin, glutathione). Long menus tend to add the research-chemical end, where evidence thins to nothing and, in some cases, lawful compounding stops entirely: see what cannot legally be compounded.

Menu length is a signal in itself. A seller offering twenty peptides is not twenty times more capable than one offering three. It has decided its business is selling injections rather than treating a condition, and that decision shows up in everything else about how it operates.

What to do at the point of sale

  1. Ask what it is approved for. For most of the top of that menu, the answer is nothing, anywhere.
  2. Ask how you would know it worked. If there is no measurable endpoint, you are buying a subscription rather than a treatment.
  3. Ask what it costs annually, not monthly. Add-ons are priced to look small next to the main product.
  4. Notice when the offer arrives. Add-ons are usually presented after you have committed to the GLP-1, which is a sales sequence rather than a clinical one.

None of this means the sellers running these menus are bad. Many run them alongside a perfectly reasonable GLP-1 service. It means the menu is a commercial artifact and should be read as one. Its ordering tells you about marketing rather than about medicine.

Frequently Asked Questions

152 of the 560 sellers we track run a peptide menu, and 127 of those also publish GLP-1 pricing. The median menu carries three items; the longest we found carries twenty.
NAD by a wide margin, at 139 sellers, then sermorelin at 109 and glutathione at 75. Those three are also among the least supported by human trials.
Because they treat specific conditions in specific people with measurable outcomes, which makes them hard to sell to everyone. The items at the top of the menu target things with no diagnostic threshold (energy, aging, recovery), where nobody is excluded and nothing can be shown to have failed.
It is a signal worth reading. A seller offering twenty peptides has decided its business is selling injections rather than treating a condition, and that decision tends to show up elsewhere in how it operates.
What it is approved for, how you would know whether it worked, and what it costs over a year rather than a month. If there is no measurable endpoint, the purchase is a subscription rather than a treatment.

References

  1. 1.GLP Watchdog. Provider register — peptide menu composition recorded from structured product fields across 560 sellers, computed August 19, 2026 GLP Watchdog register. 2026. https://glpwatchdog.org/compare

Microdosing a GLP-1: What Evidence Exists

In August 2026, 62 of the 560 sellers we tracked offered a microdose product. The published literature is letters and commentary about how to answer patients who ask for it; we identified no randomized trial.

6 min read

What a LegitScript Badge Tells You, and What It Doesn't

LegitScript certification is real, and it is also a paid commercial service that unlocks Google and Meta ads and payment processing. The badge on a seller's page is an image. This shows how to confirm one, and why 182 of our own records were unverified at our August 2026 count.

7 min read

What 519 GLP-1 Signup Funnels Look Like

Thirty percent of GLP-1 sellers show no price until you have completed a medical intake. A majority publish no list of the states they serve. What the signup pages of 519 sellers reveal.

7 min read

Who Actually Runs Your GLP-1 Brand

At our August 2026 count, 61 of the 560 sellers we tracked named one of just seven shared entities: one white-label platform, two prescriber networks, four compounding pharmacies. Comparing two brands can mean comparing two markups on the same vial.

7 min read

What Makes a Telehealth GLP-1 Prescription Legitimate

The FDA publishes seven warning signs for telehealth medicine sellers. Here they are, with what proper prescribing looks like and the one disclosure that 139 of our 560 sellers failed in an August 2026 count.

7 min read

The GLP-1 Terms You Agree To at Checkout

Four sellers ask you to waive the right to your own pharmacy. Twenty-four keep the consult fee whatever happens. What the terms pages said across 560 sellers in August 2026, and the one question to ask before paying.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

7.2

Oak

A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →